Centessa Pharmaceuticals plc (CNTA)
Oxford Ledge is still expanding full research coverage of CNTA. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Centessa develops orexin-based neurological drugs, with its lead candidate in late-stage testing before a planned acquisition by Eli Lilly.
Insider activity
5 recent insider (SEC Form 4) filings on record for CNTA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CNTA in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.